Xeris Biopharma【0A8E】銘柄情報

Xeris Biopharma Holdings Inc (0A8E) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

( - )

買値

売値

出来高

0.00 日の範囲 0.00

0.00 52 週間の範囲 0.00

時価総額

前日終値

始値

時刻

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

US$ 1,737,813

発行済株式数

172,642,055

配当利回り

PER

124.8

1 株当たり利益 (EPS)

0.06

歳入

314.85M

純利益

12.01M

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric ... Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois. 詳細を表示

セクター

業界

ウェブサイト

www.xerispharma.com

本社

Chicago, United States

設立

2026

Xeris Biopharma Holdings Inc is listed in the sector of the ロンドン証券取引所 with ticker 0A8E. The last closing price for Xeris Biopharma was -. Over the last year, Xeris Biopharma shares have traded in a share price range of US$ 0.00 to US$ 0.00.

Xeris Biopharma currently has 172,642,055 shares in issue. Xeris Biopharma has a price to earnings ratio (PE ratio) of 124.80.